Table 1.
Key model inputs.
| Parameters | Base-case Values | Ranges | Distribution | Reference |
|---|---|---|---|---|
| Cost (USD) | ||||
| Sugemalimab per 600mg | 1844.26 | 922.13-1844.26 | gamma | yaozh |
| Carboplatin per 100mg | 13.39 | 10.71-16.06 | gamma | yaozh |
| Pemetrexed per 100mg | 330.23 | 264.18-396.27 | gamma | yaozh |
| Paclitaxel per 30mg | 51.39 | 41.12-61.67 | gamma | yaozh |
| Docetaxel per 20mg | 96.65 | 77.32-115.97 | gamma | yaozh |
| Hospital management per cycle | 72.43 | 57.94-86.91 | gamma | Local charge |
| Follow-up per cycle | 199.55 | 159.64-239.46 | gamma | Local charge |
| SAEs of sugemalimab group | 23.57 | 18.86-28.28 | gamma | Local charge |
| SAEs of placebo group | 23.81 | 19.05-28.57 | gamma | Local charge |
| Best supportive care per cycle | 320.84 | 256.67-385.01 | gamma | (18) |
| Probability of SAEs (grade ≥ 3) | ||||
| Neutropenia of sugemalimab group | 0.3250 | 0.2600-0.3900 | beta | (14) |
| Rnausea and vomiting of sugemalimab group | 0.0160 | 0.0128-0.01920 | beta | (14) |
| Alopecia of sugemalimab group | 0.0030 | 0.0024-0.0036 | beta | (14) |
| Rash of sugemalimab group | 0.0060 | 0.0048-0.0072 | beta | (14) |
| Fatigue of sugemalimab group | 0.0090 | 0.0072-0.1080 | beta | (14) |
| Diarrhoea of sugemalimab group | 0.0090 | 0.0072-0.1080 | beta | (14) |
| Neutropenia of placebo group | 0.3330 | 0.2664-0.3996 | beta | (14) |
| Nausea and vomiting of placebo group | 0.0250 | 0.0200-0.0300 | beta | (14) |
| Fatigue of placebo group | 0.0060 | 0.0048-0.0072 | beta | (14) |
| Utility values | ||||
| PFS | 0.804 | 0.536-0.840 | beta | (21) |
| PD | 0.321 | 0.031-0.473 | beta | (21) |
| Disutility values | ||||
| Neutropenia | -0.20 | -0.50 to -0.15 | beta | (21) |
| Nausea and vomiting | -0.12 | -0.29 to -0.06 | beta | (21) |
| Alopecia | -0.06 | -0.26 to -0.06 | beta | (21) |
| Rash | -0.10 | -0.19 to -0.10 | beta | (21) |
| Fatigue | -0.07 | -0.49 to -0.07 | beta | (21) |
| Diarrhoea | -0.07 | -0.35 to -0.06 | beta | (21) |
| Subsequent treatment proportion of sugemalimab group | ||||
| New Anti-Cancer Therapy | 53.10% | – | – | (14) |
| Open-label Sugemalimab in crossover | 5.6% | – | – | (14) |
| Others | 41.3% | – | – | (14) |
| Subsequent treatment proportion of placebo group | ||||
| New Anti-Cancer Therapy | 25.10% | – | – | (14) |
| Open-label Sugemalimab in crossover | 27.7% | – | – | (14) |
| Others | 47.2% | – | – | (14) |
| Discount rate | 5% | 0-8% | Fixed in PSA | – |
SAEs, serious adverse events; PFS, progression-free survival; PD, progressive disease; PSA, probabilistic sensitivity analysis; sugemalimab group, sugemalimab + platinum-based chemotherapy; placebo group, placebo + platinum-based chemotherapy.